Screening and Prevention of Prostate Cancer 2021 (Part 1) - Evidence for PSA Screening

preview_player
Показать описание
In part 1 of a 3-part series, Sigrid V. Carlsson, MD, PhD, MPH, Assistant Attending Epidemiologist at Memorial Sloan Kettering Cancer Center, looks at the evidence supporting widespread prostate specific antigen (PSA) screening. She looks at a range of large studies with long follow-up that demonstrate a reduction in prostate cancer mortality of approximately 30% as a result of widespread PSA screening. Dr. Carlsson also looks at how PSA screening decisions can be made by taking other risk factors into account in order to minimize unnecessary testing. She also notes that the loss in quality-adjusted life years somewhat offsets the benefits of widespread screening. She concludes by introducing her 5 Golden Rules of testing to keep the benefits and reduce the harms.
Рекомендации по теме
Комментарии
Автор

The horror that is the PSA TEST, and the scavengers that hide ready to pounce on anything elevated, the biopsy almost killed me and left me with ED.
All I had was a temporary elevated PSA which fell back to 3.6 over 10 months with NO KIND OF TREATMENT, , BUT by then it was too late, I was shunted into biopsy JUST LIKE scores of thousands of men are worldwide each year for no reason other than

justdoesntaddup